B-Catenin and K-ras Synergize to Form Wilm's Tumor with Concurrent p53 Pathways Modulation

Simple item page
dc.contributor.otherClark, Peteren
dc.contributor.otherDeGraff, Daviden
dc.creatorHembd, Austinen
dc.date.accessioned2015-07-07T12:08:14Z
dc.date.available2015-07-07T12:08:14Z
dc.date.issued2014-02-04
dc.descriptionThe 52nd Annual Medical Student Research Forum at UT Southwestern Medical Center (Tuesday, February 4, 2014, 3-6 p.m., D1.502)en
dc.description.abstractHumans can develop pediatric kidney tumors called Wilm's tumors. If one identifies the specific genes that cause Wilm's tumor, or that concomitantly change expression levels in the tumor tissue, then diagnosis and eventually drug targets for therapy are expedited. Characterizing genetic determinants in the mouse model can help actualize these future therapies. When the genes Kras and βCatenin are overexpressed in a mouse, it develops a renal tumor histologically identical to a human Wilm's tumor. Microarray analysis on mouse tumor tissue showed modulated expression levels of gene targets in the p53 tumor suppressor pathway. Immunohistochemistry stained mice tissue specifically for p53. In tissue with Kras and βcatenin overexpression, p53 staining is positive surrounding the tumor. RT qPCR measured levels of gene expression of p53 pathway associated genes. Combination mutants βCatenin and Kras were compared with controls. This PCR array analysis identified genes, such as cJun, Traf1, and Dapk1, that had significant expression changes in the combination mutant when compared to either mutant individually. The expression is modulated in a nonadditive fashion in Kras + βcatenin mutant tissues, which can explain the phenotype of Wilm's tumor in only double mutant mice. These genes individually represent targets for therapy in the future, and together represent an identifying fingerprint for diagnosis and prediction.en
dc.description.sponsorshipSouthwestern Medical Foundationen
dc.identifier.citationHembd, A., Clark, P., & DeGraff, D. (2014, February 4). B-Catenin and K-ras synergize to form Wilm's tumor with concurrent p53 pathways modulation. Poster session presented at the 52nd Annual Medical Student Research Forum, Dallas, TX. Retrieved from https://hdl.handle.net/2152.5/1644en
dc.identifier.urihttps://hdl.handle.net/2152.5/1644
dc.language.isoenen
dc.relation.ispartofseries52nd Annual Medical Student Research Forumen
dc.subjectBasic Research and Disease Modelsen
dc.subject.meshbeta Cateninen
dc.subject.meshKidney Neoplasmsen
dc.subject.meshProto-Oncogene Proteins p21(ras)en
dc.subject.meshTumor Suppressor Protein p53en
dc.subject.meshWilms Tumoren
dc.titleB-Catenin and K-ras Synergize to Form Wilm's Tumor with Concurrent p53 Pathways Modulationen
dc.typePresentationen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Hembd-SRTP Nephrology 2013 (3).pdf
Size:
895.25 KB
Format:
Adobe Portable Document Format
Description:
PDF--public access
Download

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
297 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Annual Medical Student Research Forum